NasdaqCM - Nasdaq Real Time Price USD

Celldex Therapeutics, Inc. (CLDX)

38.53

-1.10

(-2.78%)

At close: April 18 at 4:00 PM EDT

38.00

-0.53

(-1.38%)

After hours: April 18 at 5:34 PM EDT

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—temperatures below skin temperatu

GlobeNewswire yesterday

CLDX
-2.78%
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)

The heavy selling pressure might have exhausted for Celldex (CLDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 9 days ago

CLDX
-2.78%
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy

Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 10 days ago

CLDX
-2.78%
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)

Celldex (CLDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 10 days ago

CLDX
-2.78%
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?

The consensus price target hints at a 71.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 29 days ago

CLDX
-2.78%
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 10:00 a.m. ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media” section of the Celldex website. A replay will be available for 30 days following the event. About Celldex Therapeutics, Inc.Celldex i

GlobeNewswire last month

CLDX
-2.78%
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflammation & Immunology Corporate Panel Discussion” at TD Cowen’s 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024 from 2:10 to 3:10 PM ET. A live webcast of the panel discussion will be available on the investor section of the Celldex website. A replay of the webcast

GlobeNewswire last month

CLDX
-2.78%
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share. All of the shares sold in the offering were sold by Celldex. The gross pro

GlobeNewswire last month

CLDX
-2.78%
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share. All of the shares to be sold in the offering are to be sold by Celldex. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stoc

GlobeNewswire last month

CLDX
-2.78%
Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?

Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks last month

CLDX
-2.78%
Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Celldex (CLDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks last month

CLDX
-2.78%
Celldex Therapeutics Announces Proposed Public Offering of Common Stock

HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock are being offered by the Company. The final

GlobeNewswire last month

CLDX
-2.78%
Celldex Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Celldex Therapeutics ( NASDAQ:CLDX ) Full Year 2023 Results Key Financial Results Net loss: US$141.4m (loss widened by...

Simply Wall St. last month

CLDX
-2.78%
Celldex Stock Rockets 28% On A Promising New Hives Treatment

Celldex unveiled promising results from a chronic hives treatment on Monday, and the biotech stock hit its highest point since 2021.

Investor's Business Daily last month

CLDX
-2.78%
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of 25% and 245.77%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

CLDX
-2.78%
Celldex Therapeutics Inc (CLDX) Reports Q4 and Full Year 2023 Financial Results

Biopharmaceutical Innovator Advances in Mast Cell Mediated Disease Treatments

GuruFocus.com last month

CLDX
-2.78%
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 -- Enrollment nearing completion in Phase 2 CIndU study; Data expected 2H 2024 -- Phase 2 PN study expected to start in early 2024; Positive Phase 1 PN data reported in oral presentation at WCI 2023 - HAMPTON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported f

GlobeNewswire last month

CLDX
-2.78%
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid onset within 2 weeks -- Similar improvement in omalizumab-experienced/refractory and omalizumab-naïve disease consistent with unique mechanism of action -- Favorable safety profile -- 52 week results and Phase 3 CSU trial initiations anticipated in 2024 -- Company to host webcast February 25th at 9:45 a

GlobeNewswire last month

CLDX
-2.78%
TipRanks’‘Perfect 10’ List: These 2 Biotech Stocks Look Compelling at Current Levels

When you’re looking for a stock sector with potential for big gains, you can’t help but look at the biotechs. These stocks are famous for their long product lead times and high overhead – bringing a new pharmaceutical to market can take years, and cost tens of millions of dollars – but for investors, their attraction lies in their potential. One piece of good news, be it a positive clinical trial result or meeting a regulatory milestone, can give a major boost to the share price. The trick is fi

TipRanks last month

CLDX
-2.78%
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 9:00 a.m. ET. A webcast of the presentation will be available on the "Events & Presentations" of the "Investors & Media" section of the Celldex website. A replay will be available for 30 days following the event. About Celldex Therapeuti

GlobeNewswire 2 months ago

CLDX
-2.78%

Performance Overview

Return	CLDX	S&P 500
YTD	-2.85%	+5.06%
1-Year	+18.74%	+20.71%
3-Year	+63.61%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Celldex Therapeutics, Inc. (CLDX)

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)

All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy

Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)

Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Celldex Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Celldex Stock Rockets 28% On A Promising New Hives Treatment

Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates

Celldex Therapeutics Inc (CLDX) Reports Q4 and Full Year 2023 Financial Results

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

TipRanks’‘Perfect 10’ List: These 2 Biotech Stocks Look Compelling at Current Levels

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Performance Overview